Kopran Q4 FY26 Results: PAT Rs 19 Cr

Kopran Q4 FY26 results were declared on May 19, 2026. Kopran reported PAT of Rs 19 crore up 90.0% YoY from Rs 10 crore in Q4 FY25, on revenue of Rs 234 crore for the quarter ended March 31, 2026. Kopran is a Pharmaceuticals company listed on Indian stock exchanges. This article covers the complete Kopran Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Kopran.

Click Here – Get Free Investment Predictions

Kopran Q4 FY26 Financial Highlights

Metric	Q4 FY26	Notes
PAT	Rs 19 crore	up 90.0% YoY from Rs 10 crore in Q4 FY25
Revenue	Rs 234 crore	for the quarter ended March 31, 2026

Note: Q4 FY26 PAT Rs 19 crore (+90% YoY) on revenue Rs 234 crore. API and formulations manufacturer. Strong API export growth.

Kopran Q4 FY26 Performance Analysis

The Kopran Q4 FY26 results reflect Kopran’s operational performance during the January to March 2026 quarter. The company operates in the Pharmaceuticals space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.

Screen the best stocks on the Univest Screener.

Investors tracking Kopran Q4 FY26 will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Kopran on the Univest Screener for live fundamentals and real-time updates.

Key Business Factors for the company

Revenue and Operational Performance

the listed company performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the Pharmaceuticals sector during this period.

Profitability and Margin Trends

The group PAT of Rs 19 crore is up 90.0% YoY from Rs 10 crore in Q4 FY25. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.

India Economic Context for Kopran

The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Kopran, operating in the Pharmaceuticals space, this macro backdrop supported demand conditions during the quarter.

FY27 Outlook and Growth Drivers

Following the business results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The Pharmaceuticals sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the firm

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.